TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

How valve type and anesthesia strategy affect 1-year TAVR outcomes

Researchers in Germany explored data from more than 400 TAVR patients, sharing their findings in the Journal of the American College of Cardiology. 

Thumbnail

Risk of a permanent pacemaker after valve-in-valve TAVR is low, especially when using newer heart valves

The findings, published in the Journal of the American College of Cardiology, focused on data from the VIVID registry.

SCAI 2021: Medtronic pleased with 30-day data on Evolut TAVR systems

Researchers presented 30-day data at the SCAI 2021 Scientific Sessions, highlighting the "excellent" outcomes and the importance of constantly working to improve patient care. 

Thumbnail

SCAI 2021: 98% of new TAVR programs developed in metropolitan areas

Researchers tracked 554 TAVR programs that opened from 2012 to 2018, sharing their findings at the SCAI 2021 Scientific Sessions.

Thumbnail

Surgical risk scores may not be needed when considering TAVR

Recent TAVR research suggests clinicians should focus on other key factors such as the patient's age and life expectancy. 

Thumbnail

Risk of death, stroke increases with age for TAVR patients

The risk of post-TAVR pacemaker implantation also goes up when treating elderly patients. 

COVID-19 patients undergoing TAVR may face a higher risk of death

The study included data from more than 3,000 TAVR patients who received care from January 2020 to January 2021. 

Thumbnail

Specialists complete first procedure in historic head-to-head TAVR study

The global trial is designed to compare TAVR systems from Medtronic and Edwards Lifesciences when treating patients with small annuli.

Displaying 409 - 416 of 469

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.